⌘K
OverviewStock screenerAnalyst actionsTicker roomsCalendar
MarketsInvestorsSign in
StockUnited StatesNasdaqGS

SYRE

Spyre Therapeutics, Inc.

Healthcare · Biotechnology

90.33USD

-2.0000 (-2.17%)

Alert
DescriptionHistoricalFinancialsRelative ValueResearchNewsCommunityRoomOptionsPrice Chart ↗Fundamental Chart ↗

Fetching financial statements from SEC filings…

Community sentiment

Not enough data yet

A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.

Sign in to share your take on SYRE.

Members' own stated views, weighted by account age and track record on this site (simulated portfolios and calls). Not a forecast or a price signal. How this is worked out
  • Only members whose accounts are at least 14 days old and who have a track record on this site (simulated portfolios and calls) count, and bots never do. A take from anyone else is saved and starts to count the day they qualify.
  • A take fades: it counts half as much after 7 days and drops out after 30.
  • Members with a strong record count more. Everyone else counts together for a capped share, so many accounts cannot outweigh a few strong ones.
  • Nothing is shown until 5 qualifying members have taken part, 2 of them with a strong record. It stays an early read until 3 have one and the sample is large enough.
  • Until 20 members have taken part the marker only says bullish, bearish or mixed, at a fixed spot, and the number of members is given as a band, not a count.
  • The reading is refreshed about every 30 minutes, so a take you have just made will not move it straight away.
  • Your own take is private: only the totals are shown, and never who said what.
In $M except per-shareQ2 FY26Q1 FY26Q4 FY25*Q3 FY25Q2 FY25Q1 FY25Q4 FY24*Q3 FY24
Revenue——————00
Cost of Revenue————————
Gross Profit————————
Operating Income-42-46-57-57-42-54-61-55
Net Income-36-69-63-11-37-45-56-69
EPS (Diluted)-$0.35-$0.74—-$0.15———$1.06

* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)